- Home
- AZN
AZN
AstraZeneca PLC
as 10-07-2025 3:28pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 252.9B | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 5.31 | EPS Growth: | 28.86 |
| 52 Week Low/High: | $61.24 - $86.57 | Next Earning Date: | 11-11-2025 |
| Revenue: | $56,501,000,000 | Revenue Growth: | 15.00% |
| Revenue Growth (this year): | 10.87% | Revenue Growth (next year): | 6.12% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Investor's Business Daily
10 hours ago
Best Stocks To Watch: Two New IPOs, Pharma Titan AstraZeneca And Electrical Grid Play Emcor Trade Near Buy Points
Simply Wall St.
10 hours ago
AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher
ACCESS Newswire
11 hours ago
My Green Lab Thanks Board Member Penny James for Her Service and Welcomes Liz Chatwin to the Board of Directors
Zacks
12 hours ago
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
Business Wire
13 hours ago
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
The Telegraph
a day ago
AstraZeneca threatens to stop investing in Britain
PR Newswire
a day ago
Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth
Reuters
a day ago
AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.